Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibroti...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Sandra, Ortiz, Cristina, Bachtler, Nadine, Gu, Wenyi, Grünewald, Leon D., Kraus, Nico, Schierwagen, Robert, Hieber, Christoph, Meier, Caroline, Tyc, Olaf, Joseph Brol, Maximilian, Uschner, Frank Erhard, Nijmeijer, Bart, Welsch, Christoph, Berres, Marie‐Luise, Garcia‐Ruiz, Carmen, Fernandez‐Checa, Jose Carlos, Trautwein, Christian, Vogl, Thomas J., Zeuzem, Stefan, Trebicka, Jonel, Klein, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Liver Failure/Cirrhosis/Portal Hypertension
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026969/
https://www.ncbi.nlm.nih.gov/pubmed/35993369
http://dx.doi.org/10.1002/hep.32746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026969/
https://www.ncbi.nlm.nih.gov/pubmed/35993369
http://dx.doi.org/10.1002/hep.32746

Ejemplares similares